Peptide-Boronic Acid Inhibitors of Flaviviral Proteases: Medicinal Chemistry and Structural Biology.Nitsche, C., Zhang, L., Weigel, L.F., Schilz, J., Graf, D., Bartenschlager, R., Hilgenfeld, R., Klein, C.D.
(2017) J. Med. Chem. 60: 511-516
- PubMed: 27966962
- DOI: 10.1021/acs.jmedchem.6b01021
- PubMed Abstract:
A thousand-fold affinity gain is achieved by introduction of a C-terminal boronic acid moiety into dipeptidic inhibitors of the Zika, West Nile, and dengue virus proteases. The resulting compounds have K <sub>i </sub> values in the two-digit nanomola ...
A thousand-fold affinity gain is achieved by introduction of a C-terminal boronic acid moiety into dipeptidic inhibitors of the Zika, West Nile, and dengue virus proteases. The resulting compounds have K i values in the two-digit nanomolar range, are not cytotoxic, and inhibit virus replication. Structure-activity relationships and a high resolution X-ray cocrystal structure with West Nile virus protease provide a basis for the design of optimized covalent-reversible inhibitors aimed at emerging flaviviral pathogens.
Institute of Biochemistry, Center for Structural and Cell Biology in Medicine, University of Lübeck , Ratzeburger Allee 160, 23562 Lübeck, Germany.,Medicinal Chemistry, IPMB, Heidelberg University , INF-364, 69120 Heidelberg, Germany.,German Center for Infection Research (DZIF) , Sites Hamburg-Lübeck-Borstel-Riems and Heidelberg, Germany.,Department of Infectious Diseases, Molecular Virology, Heidelberg University , INF-345, 69120 Heidelberg, Germany.